手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按作者
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
36条
与
Ren
有关的结果
Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms
2021年 发布于
British Journal of Clinical Pharmacology
87卷 第7期
D'Agate
S. Chavan
C. Manyak
M. Palacios-Moreno
J. M. Oelke
M. Michel
M. C. Roehrborn
C. G. Della Pasqua
O.
Benign prostatic hyperplasia
acute urinary retention
meta-analysis
文献简介
原文链接
New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes
2021年 发布于
European Urology Open Science
33卷 第期
Checcucci
E. Veccia
A. De Cillis
S. Piramide
F. Volpi
G. Amparore
D. Pecoraro
A. Piana
A. Granato
S. Verri
P. Sica
M. Meziere
J. Carbonaro
B. Piscitello
S. Zamengo
D. Cacciamani
G. Okhunov
Z. Puliatti
S. Taratkin
M. Marenco
J. Rivas
J. G. Veneziano
D. Carbonara
U. Russo
G. I. De Luca
S. Manfredi
M. Fiori
C. Autorino
R. Porpiglia
F.
Minimally Invasive Surgical Treatment
Benign prostatic hyperplasia
Systematic review
文献简介
原文链接
Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association
2021年 发布于
Progrès en Urologie
31卷 第5期
French Urology Association
Guidelines
Benign prostate hyperplasia
Benign prostatic obstruction
Lower urinary tract symptoms
Surgery
Interventional management
文献简介
原文链接
Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms
2020年 发布于
British Journal of Clinical Pharmacology
86卷 第8期
D'Agate
S. Wilson
T. Adalig
B. Manyak
M. Palacios-Moreno
J. M. Chavan
C. Oelke
M. Roehrborn
C. Della Pasqua
O.
Individual International Prostate Symptom Score
Benign prostatic hyperplasia
Meta-analysis
文献简介
原文链接
A Systematic Review and Meta-Analysis Evaluating the Safety and Efficacy of the Endoscopic Treatment Options for Benign Prostatic Enlargement
2019年 发布于
Journal of Urology
201卷 第4期
Teles
S. Amaral
B. Carneiro
A. Kayano
P. Cha
J. Alfer
W. Monteiro
J. Gil
A. Barbosa
A. Partezani
A. Lourenco
D. Lemos
G. Wroclawski
M.
Endoscopic Treatment
Benign Prostatic Enlargement
Meta-Analysis
文献简介
原文链接
Comparison Between Minimally Invasive Simple Prostatectomy and Open Simple Prostatectomy for Large Prostates: A Systematic Review and Meta-Analysis of Comparative Trials
2019年 发布于
J Endourol
33卷 第9期
Li
J. Cao
D. Peng
L.
Ren
Z. Gou
H. Li
Y. Wei
Q.
Blood Transfusion
Clinical Trials as Topic
Humans
Length of Stay
Male
Minimally Invasive Surgical Procedures
Operative Time
Prostate
Prostatectomy
Prostatic Hyperplasia
Quality of Life
Treatment Outcome
Urinary Retention
*benign prostatic hyperplasia
*laparoscopic
*minimally invasive simple prostatectomy
*open simple prostatectomy
*robotic
文献简介
原文链接
Therapeutic efficacy of orally administered pollen for nonallergic diseases: An umbrella review
2019年 发布于
Phytother Res
33卷 第11期
Antonelli
M. Donelli
D. Firenzuoli
F.
Administration
Oral
Chronic Disease
Flowers/physiology
Humans
Male
Medicine
Traditional
Phytotherapy
Plant Extracts/*administration & dosage
Pollen/*physiology
Prostatic Hyperplasia/drug therapy
Prostatitis/drug therapy
Treatment Outcome
clinical practice
efficacy
evidence-based complementary and alternative medicine
phytotherapy
pollen
review
文献简介
原文链接
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(®) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies
2018年 发布于
BJU Int
122卷 第6期
Vela-Navarrete
R. Alcaraz
A. Rodríguez-Antolín
A. Miñana López
B. Fernández-Gómez
J. M. Angulo
J. C. Castro Díaz
D. Romero-Otero
J. Brenes
F. J. Carballido
J. Molero García
J. M. Fernández-Pro Ledesma
A. Cózar Olmos
J. M. Manasanch Dalmau
J. Subirana Cachinero
I. Herdman
M. Ficarra
V.
Androgen Antagonists/*pharmacology
Biomarkers/urine
Humans
Inflammation/urine
Lower Urinary Tract Symptoms/physiopathology
Male
Observational Studies as Topic
Phytotherapy
Plant Extracts/*pharmacology
Prostatic Hyperplasia/physiopathology/urine
Randomized Controlled Trials as Topic
Serenoa
Treatment Outcome
* Serenoa repens
*Luts/bph
*Permixon
*hexanic extract
*meta-analysis
*systematic review
文献简介
原文链接
A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate
2017年 发布于
Urol Int
98卷 第4期
Ren
J. Lai
S. Jiang
Z. Xu
X. Diao
T. Thiruchelvam
N. Zhang
G.
5-alpha Reductase Inhibitors/pharmacology
Blood Loss
Surgical/*prevention & control
Blood Transfusion
Dutasteride/*pharmacology
Hemoglobins/analysis
Humans
Male
Microcirculation
Prospective Studies
Prostate
Prostatic Hyperplasia
Randomized Controlled Trials as Topic
Retrospective Studies
*Transurethral Resection of Prostate
Treatment Outcome
Vascular Endothelial Growth Factor A/metabolism
Benign prostatic hyperplasia
Dutasteride
Intraoperative blood loss
Meta-analysis
Transurethral resection of the prostate
文献简介
原文链接
Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
2016年 发布于
World Journal of Urology
34卷 第9期
Lin
Y. C. Wu
X. Xu
A. B.
Ren
R. Zhou
X. Q. Wen
Y. Zou
Y. Gong
M. C. Liu
C. X. Su
Z. X. Herrmann
T. R. W.
Transurethral enucleation of the prostate
transvesical open prostatectomy
benign prostatic hyperplasia
meta-analysis
文献简介
原文链接
Urinary human papilloma virus infection and bladder cancer risk: A systematic review and a prisma-compliant meta-analysis
2022 年 发布于
Int J Nurs Pract
13 卷 第 4 期
Garcia-Rojo D.
Munoz-Rodriguez J.
Centeno C.
Dominguez A.
Prera A.
Abad C.
Vicente E.
Gonzalez-Sala J. L.
Hannaoui N.
Capdevila M.
De Verdonces L.
Ferran A.
Pla C.
Azuara P.
Cuadrench S.
Zegri M. E.
Prats J.
非肌层浸润性膀胱癌
卡介苗
维持治疗
诱导治疗
文献简介
原文链接
A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ
2022 年 发布于
Immunotherapy
14 卷 第 7 期
Straccia P.
Fiorentino V.
Martini M.
Pierconti F.
*Cystectomy
Humans
*Neoadjuvant Therapy
Neoplasm Staging
Treatment Outcome
Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery
文献简介
原文链接
International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup
2022 年 发布于
Pract Radiat Oncol
12 卷 第 6 期
Verghote F.
Sargos P.
Christodouleas J. P.
Murthy V.
Baumann B. C.
Dirix P.
Berghen C.
Paelinck L.
Vercauteren T.
Fonteyne V.
文献简介
原文链接
Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)
2022 年 发布于
Onkourologiya
18 卷 第 2 期
Novikov R. V.
Novikov S. N.
Novikov A. I.
Petrov S. B.
Protsenko S. A.
Protoshchak V. V.
Popov S. V.
Shkolnik M. I.
Shpilenya E. S.
Kurenkov A. V.
Sokurenko V. P.
Orlova R. V.
Nosov A. K.
Koroi V. D.
Latipoval D. K.
Mikheeva Y. V.
Kanaev S. V.
Humans
*Carcinoma
Transitional Cell/secondary
*Urinary Bladder Neoplasms/pathology
文献简介
原文链接
Bipolar versus monopolar transurethral resection of non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials
2021 年 发布于
J Pers Med
31 卷 第 6 期
Xie K.
Cao D.
Wei Q.
Ren
Z.
Li J.
Li Y.
Fu M.
Carcinoma
Transitional Cell/*classification/*genetics/mortality
Humans
Predictive Value of Tests
Survival Rate
Treatment Outcome
Urinary Bladder Neoplasms/*classification/*genetics/mortality
Bladder cancer
Molecular classification
Molecular subtype
Prognosis
Progression
Urothelial carcinoma
文献简介
原文链接
Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer
2021 年 发布于
Front Surg
47 卷 第 2 期
Kourbanhoussen K.
McMartin C.
Lodde M.
Zlotta A.
Bryan R. T.
Toren P.
Cystectomy/*methods
Humans
Survival Analysis
Urinary Bladder Neoplasms/mortality/*surgery
Bladder cancer
Delay
Radical cystectomy
Survival
文献简介
原文链接
Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature
2021 年 发布于
PLoS One
49 卷 第 9 期
Crocetto F.
di Zazzo E.
Buonerba C.
Aveta A.
Pandolfo S. D.
Barone B.
Trama F.
Caputo V. F.
Scafuri L.
Ferro M.
Cosimato V.
Fusco F.
Imbimbo C.
Di Lorenzo G.
Bayes Theorem
Cystectomy
Humans
Laparoscopy
Robotic Surgical Procedures
Urinary Bladder Neoplasms/*surgery
文献简介
原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text
2021 年 发布于
Can Urol Assoc J
15 卷 第 8 期
Bhindi B.
Kool R.
Kulkarni G. S.
Siemens D. R.
Aprikian A. G.
Breau R. H.
Brimo F.
Fairey A.
French C.
Hanna N.
Izawa J. I.
Lacombe L.
McPherson V.
Ren
don R. A.
Shayegan B.
So A. I.
Zlotta A. R.
Black P. C.
Kassouf W.
Guidelines as Topic
Humans
Immunotherapy/*methods
Societies
Medical/*standards
Urinary Bladder Neoplasms/*drug therapy
antineoplastic protocols
immunotherapy
urinary bladder neoplasms
urologic neoplasms
Pfizer
AstraZeneca
Nektar
Seattle Genetics
DragonFly Therapeutics
Non-CME
services: Genentech
AstraZeneca
Merck
Seattle Genetics
Contracted research:
Genentech
Merck
AstraZeneca
Nektar
Seattle Genetics
Immunomedics.
PCB─Consulting fees: AbbVie
Asieris Pharmaceuticals
Astellas
AstraZeneca
Bayer
Biosyent
Bristol-Myers Squibb
EMD Serono
Ferring
Fergene
H3
Biomedicine
Janssen
Merck
Roche
Sanofi
TerSera
Urogen
Contracted research:
iProgen. MTC─Consulting fees: Pfizer
EMD Serono
AstraZeneca
Exelixis
Eisai
Seattle Genetics
Astellas
Contracted research: Exelixis
Pfizer/EMD Serono
Janssen
Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus
group 2020. MDG─Consulting fees: Inovio
NuMab
Janssen
Merck
GlaxoSmithKline
Genentech
Bristol-Myers Squibb
Seattle Genetics
Dracen
Dragonfly
Astellas
Novartis
Pfizer
AstraZeneca
Incyte
Dendreon
Eli Lilly
EMD Serono
Aileron
Therapeutics
Ownership interest: Rappta Therapeutics
NPI: 1639140668.
PG─Consulting fees: AstraZeneca
Dyania Health
EMD Serono
Immunomedics
Janssen
Merck
Mirati Therapeutics
Genentech
Pfizer
Seattle Genetics
Contracted Research: Bavarian Nordic
Bristol-Myers Squibb
Clovis Oncology
Debiopharm
Immunomedics
Pfizer
Merck
QED Therapeutics
GlaxoSmithKline
Kure
It Cancer Research
Mirati Therapeutics. SG─Consulting fees: Merck
Bristol-Myers
Squibb
Janssen
Seattle Genetics
AstraZeneca
Contracted research:
Bristol-Myers Squibb
Pfizer
Non-CME services: Exelixis. CJH─Consulting fees:
Astellas
Bristol-Myers Squibb
Genentech
Merck
Eisai
Seattle Genetics
2bPrecise
Non-CME services: Astellas
Bristol-Myers Squibb
Genentech
Eisai
Seattle Genetics. AMK─Consulting fees: Abbott Molecular
Arquer
ArTara
Asieris
AstraZeneca
BioClin Therapeutics
Bristol-Myers Squibb
Cepheid
Cold Genesys
Eisai
Engene
Inc.
Ferring
FerGene
Imagin
Janssen
MDxHealth
Medac
Merck
Pfizer
Photocure
ProTara
Roviant
Seattle Genetics
Sessen Bio
Theralase
TMC
Innovation
US Biotest
Contracted research: Adolor
Bristol-Myers Squibb
FKD
Industries
Heat Biologics
Merck
Photocure
SWOG/NIH
SPORE
AIBCCR
Clinical
trials: FKD
Merck
Bristol-Myers Squibb
Photocure
SWOG
Adolor
Heat
Biologics
Laboratory research: NIH
SPORE
AIBCCR
Educational grant: CEC
Oncology
Editorial board: European Urology Oncology
Journal of Urology
UroToday
President of organization: International Bladder Cancer Network (IBCN)
International Bladder Cancer Group (IBCG)
IP Rights: CyPRIT (Cytokine Predictors
of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center.
LPL─Consulting fees: Pfizer Advisory Nursing board
2018
Lecture/Speaker/Expert
Panel: ASCO Bladder Program 2019
Pfizer learning day 2019
ASCO Bladder Program
Panel Member and Faculty 2019
Pfizer Learning Day Speaker 2019
BCAN Webinar
Faculty 11/2020. JJM─Consulting fees: AstraZeneca
Ferring
Janssen
Nucleix
Foundation Medicine
Contracted research: Epizyme
Tesaro
Abbvie
Teaching an
endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca
Infinity Pharma
Pfizer
Flatiron
Genentech
Merck
Seattle Genetics
Contracted research:
Astellas
Bristol-Myers Squibb
Genentech
Merck. JER─Consulting fees: Merck
Bristol-Myers Squibb
AstraZeneca
Astellas
Seattle Genetics
Boehringer
Ingelheim
Bayer
Pfizer
Roche/Genentech
Mirati
QED Therapeutics
Janssen
Pharmacyclics
GlaxoSmithKline
Contracted research/Clinical trial funding:
Seattle Genetics
Astellas
Roche/Genentech
Bayer
AstraZeneca
QED
Therapeutics. NS─Consulting fees: Amgen
Astellas
AstraZeneca
Bayer
Bristol-Myers Squibb
Dendreon
Fergene
Ferring
Janssen
Merck
Myovant
Nymox
Pfizer
Sanofi/Genzyme
Sesen Bio
Sun Pharma
Tolmar. GDS─Consulting fees:
Merck
Janssen
Ferring
Bristol-Myers Squibb
Pfizer
Genentech
Epivax
Oncology
AstraZeneca
Fidia
Cold Genesys
EnGene Bio
Aduro Biotech
Dendreon
FKD Therapies
CiClomed
Seattle Genetics
Urogen
PhotoCure. SITC staff:
SMW—Shares owned: Pacific Biosciences
Editas Medicine
EG
AK
BL
LL─Nothing to
disclose.
文献简介
原文链接
Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review
2021 年 发布于
Actas Urol Esp (Engl Ed)
8 卷 第 9-10 期
Li M.
Toniolo J.
Nandurkar R.
Papa N.
Lawrentschuk N.
Davis I. D.
Sengupta S.
*Cystectomy/methods
*Enhanced Recovery After Surgery
Humans
Length of Stay
Treatment Outcome
Urinary Bladder Neoplasms/*surgery
Cystectomy
Enhanced Recovery After Surgery
Enhanced recovery
Outcomes
文献简介
原文链接
Predictive value of beta-catenin in bladder cancer: a systematic review and meta-analysis
2020 年 发布于
European Urology
3 卷 第 3-4 期
Ren
J.
Yang Y. D.
Peng T. F.
Xu D.
Circulating Tumor DNA/*analysis/blood/urine
Humans
Reproducibility of Results
Sensitivity and Specificity
Urinary Bladder Neoplasms/*diagnosis/pathology
CfDNA
biomarkers
diagnosis
meta-analysis
文献简介
原文链接
首页
1
2
下一页
尾页
共36条,每页显示
20条
50条
100条
跳转至第
页
确定